PFE vs MRK
Big pharma. Compare price, valuation, growth, profitability, and balance-sheet quality — all in one view.
Highlighted values indicate the better reading for that metric, where direction is unambiguous. Lower is generally better for valuation multiples and leverage; higher is better for growth, margin, and cash-flow metrics. Educational data only, not investment advice.
Next research paths
Open the full PFE stock page with chart, fundamentals, FAQ, and news context.
Open the full MRK stock page with chart, fundamentals, FAQ, and news context.
Check the next earnings date and reporting history for PFE.
Move from side-by-side comparison into open desk notes and live market context.
PFE vs MRK — common questions
Is PFE or MRK the better stock?
Across the valuation, growth, and profitability metrics compared on this page, PFE shows the stronger reading on more of them (7 vs 5). A metric tally is not a recommendation — the right pick depends on your time horizon and risk tolerance.
Which is bigger, PFE or MRK?
MRK has the larger market capitalization — PFE is about $138.44B versus $317.77B for MRK.
Which grows faster, PFE or MRK?
PFE shows the faster year-over-year revenue growth — PFE at 5.4% versus 4.9% for MRK.
Is PFE or MRK cheaper?
On forward price-to-earnings, PFE trades at the lower multiple — PFE at 8.6x versus 13.5x for MRK.
What is the difference between PFE and MRK?
Pfizer, Inc. operates in the Healthcare sector, while Merck & Company, Inc. operates in the Healthcare sector. This page compares the two across price, valuation multiples, growth, margins, and balance-sheet quality.
Go deeper than a side-by-side.
Add PFE and MRK to your Meridian watchlist for live alerts, AI-driven setups, and full earnings coverage.